As a part of the Hetero Group, our Biologics vertical, comes with a rich legacy - Proven capabilities in the development, manufacturing and
marketing of chemical intermediates, APIs, ARVs and Finished Dosage Formulations.
With leadership in chemical therapeutics, Hetero continues to lead from the front in the development and manufacturing of Biopharmaceuticals
using novel technologies.
Hetero has 36 state-of-the-art manufacturing facilities strategically located worldwide. And a majority of our facilities have been
successfully audited and approved by stringent regulatory authorities like US FDA, EU, TGA-Australia, MCC-South Africa and others. Our portfolio
includes 300 plus products encompassing major therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis,
Nephrology, Urology, Diabetes, Ophthalmology, Hepatology and Immunology etc.
Hetero has a strong global presence in over 126 countries and focusses on making affordable medicines accessible to patients worldwide.
Dr. B.P.S.Reddy, Chairman, Hetero Group of Companies
It was the keenness to ensure good health for all that drove Dr. B.P.S Reddy to set up Hetero in 1993. A visionary scientist, Dr. B.P.S Reddy also had vast leadership experience in Research and Development, manufacturing and marketing with leading pharmaceutical companies. His scientific expertise paved the way for research breakthroughs while his business acumen enabled Hetero to become a global player with strong capabilities in manufacturing and marketing.
Under Dr. B.P.S Reddy’s leadership, Hetero has risen to become the largest closely held pharmaceutical company in India. It is recognized as a world leader in the production of affordable Anti-retroviral drugs besides being known for offering high quality medicines across major therapies.
Dr. Vamsi Krishna Bandi, Managing Director, Hetero Group of Companies
Dr. Vamsi Krishna is the Managing Director at Hetero and oversees various business functions in technical and commercial areas. He primarily focuses on building the formulations business globally with special emphasis on key markets such as US, EU and emerging markets. He is passionate to take Hetero to the next level by strengthening the organisation’s capabilities in Oncology and Biologics.
Dr. Vamsi Krishna holds a PhD in Environmental Science & Technology from JNTUH, an MS in Chemical Engineering from Stanford University and a Bachelor’s Degree in Chemical Engineering from Institute of Chemical Technology, popularly known as UDCT in Mumbai.